Impact of Bevacizumab
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bevacizumab
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Disease-Free Survival
Docetaxel
/ administration & dosage
Erlotinib Hydrochloride
/ administration & dosage
Female
Humans
Male
Middle Aged
Neoplasm Staging
Treatment Outcome
Bevacizumab
Hellenic Cooperative Oncology Group
erlotinib
non-small cell lung cancer
tumor metrics
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
12
02
2020
revised:
24
02
2020
accepted:
27
02
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
11
4
2020
Statut:
ppublish
Résumé
The mechanism of action of bevacizumab and erlotinib is quite different in the treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare the two targeted therapies in terms of sequential tumor response metrics. Parameters of radiological tumor response evaluation were assessed at baseline and periodically in 58 patients receiving either bevacizumab plus platinum-based chemotherapy (N=25) or erlotinib (N=33). Bevacizumab-treated patients had lower longest diameter at best response compared to the erlotinib group (p=0.011). The longest diameter, tumor volume and density significantly decreased from baseline to best response for the entire cohort and bevacizumab-treated patients; no difference was found in the erlotinib group. Treatment with bevacizumab substantially improved tumor metrics between baseline and each cycle of treatment, as well as between baseline and best response, in patients with advanced NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
The mechanism of action of bevacizumab and erlotinib is quite different in the treatment of advanced non-small cell lung cancer (NSCLC). This study sought to compare the two targeted therapies in terms of sequential tumor response metrics.
PATIENTS AND METHODS
METHODS
Parameters of radiological tumor response evaluation were assessed at baseline and periodically in 58 patients receiving either bevacizumab plus platinum-based chemotherapy (N=25) or erlotinib (N=33).
RESULTS
RESULTS
Bevacizumab-treated patients had lower longest diameter at best response compared to the erlotinib group (p=0.011). The longest diameter, tumor volume and density significantly decreased from baseline to best response for the entire cohort and bevacizumab-treated patients; no difference was found in the erlotinib group.
CONCLUSION
CONCLUSIONS
Treatment with bevacizumab substantially improved tumor metrics between baseline and each cycle of treatment, as well as between baseline and best response, in patients with advanced NSCLC.
Identifiants
pubmed: 32234902
pii: 40/4/2095
doi: 10.21873/anticanres.14168
doi:
Substances chimiques
Docetaxel
15H5577CQD
Bevacizumab
2S9ZZM9Q9V
Erlotinib Hydrochloride
DA87705X9K
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2095-2106Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.